The Uncertain Path Forward for Psychedelic Medicine

For a while, it looked like the psychedelic drug MDMA was poised to become an approved treatment for post-traumatic stress disorder. Now, after being rejected by the US Food and Drug Administration, MDMA faces an uphill battle to becoming legalized as medicine.

In 2017, the FDA granted MDMA “breakthrough therapy” status, a designation that recognizes a new drug’s potential benefits and expedites its review. Then came promising data from two clinical trials showing that MDMA reduced PTSD symptoms in people when it was used alongside talk therapy. The approach won over military veterans and dozens of members of Congress.

But after a disastrous meeting with

→ Continue reading at Wired - Science

More from author

Related posts

Advertisment

Latest posts

TikTok fights for survival in latest filing as ban approaches

A TikTok sign is displayed on their building in Culver City, Calif in...

‘I felt like a celebrity’: Personalized ads hit China metro stations as operators scramble for cash | CNN Business

Editor’s Note: Sign up for CNN’s Meanwhile in China newsletter which explores what you need to know about the country’s rise and how it impacts...

I Am an Investor in OpenAI — Here’s What Other Investors Must Consider About The Biggest Risks and Benefits of AI

Opinions expressed by Entrepreneur contributors are their own. While AI has been in existence since the 1950s, it has only just recently...